C
Calidi Biotherapeutics, Inc. (CLDI)
ASE – Real Time Price. Currency in USD
0.27
-0.01 (-3.75%)
At close: Mar 27, 2026, 3:59 PM EDT
0.27
-0.00 (-1.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
ASE – Real Time Price. Currency in USD
0.27
-0.01 (-3.75%)
At close: Mar 27, 2026, 3:59 PM EDT
0.27
-0.00 (-1.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.12 | 6.05 | 10 | |
| Quick ratio | 2.12 | 5.63 | 10 | |
| Debt to Equity | 0.48 | 0.30 | 7.0 | |
| Debt to Assets | 0.24 | 1.04 | 7.0 | |
| Interest coverage | -123.12 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 45K | N/A | N/A | N/A |
| Gross Profit | N/A | -229K | -1M | -2M | -2M |
| Operating Income | -2M | -23M | -29M | -22M | -20M |
| Net Income | 3M | -25M | -29M | -22M | -26M |
| EBITDA | -2M | -23M | -28M | -20M | -18M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 51.85 | 5.5 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | 79.12 | 5.5 |
| Next year | N/A | 25.81 | 5.5 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -89.35 | -11.05 | 13.61 | 5.0 |
| Y/Y | 999 | -114.12 | 71.67 | 13.87 | 7.3 |
| 3y average | 632.67 | -280.47 | N/A | -411.1 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 4.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $10.5M significantly exceed its total debt $3.3M, ensuring strong financial flexibility
Total current assets $11.0M exceed Total current liabilities $5.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.5) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-123.1x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$4.3M limits the company's ability to reinvest or pay down debt